Effect of Dexketoprofen on the Disposition Kinetics of Moxifloxacin in Plasma and Lung in Male and Female Rats.

IF 2.1 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Teslime Erdogan, Halis Oguz, Orhan Corum
{"title":"Effect of Dexketoprofen on the Disposition Kinetics of Moxifloxacin in Plasma and Lung in Male and Female Rats.","authors":"Teslime Erdogan, Halis Oguz, Orhan Corum","doi":"10.2174/0113892002282271231219044508","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The simultaneous use of NSAIDs and antibiotics is recommended for bacterial diseases in human and veterinary medicine. Moxifloxacin (MFX) and dexketoprofen (DEX) can be used simultaneously in bacterial infections. However, there are no studies on how the simultaneous use of DEX affects the pharmacokinetics of MFX in rats.</p><p><strong>Objectives: </strong>The aim of this study was to determine the effect of DEX on plasma and lung pharmacokinetics of MFX in male and female rats.</p><p><strong>Methods: </strong>A total of 132 rats were randomly divided into 2 groups: MFX (n=66, 33 males/33 females) and MFX+DEX (n=66, 33 females/33 males). MFX at a dose of 20 mg/kg and DEX at a dose of 25 mg/kg were administered intraperitoneally. Plasma and lung concentrations of MFX were determined using the highperformance liquid chromatography-UV and pharmacokinetic parameters were evaluated by noncompartmental analysis.</p><p><strong>Results: </strong>Simultaneous administration of DEX increased the plasma and lung area under the curve from 0 to 8 h (AUC<sub>0-8</sub>) and peak concentration (C<sub>max</sub>) of MFX in rats, while it significantly decreased the total body clearance (CL/F). When female and male rats were compared, significant differences were detected in AUC<sub>0-8</sub>, C<sub>max</sub>, CL/F and volume of distribution. The AUC<sub>0-8lung</sub>/AUC<sub>0-8plasma</sub> ratios of MFX were calculated as 1.68 and 1.65 in female rats and 5.15 and 4.90 in male rats after single and combined use, respectively.</p><p><strong>Conclusion: </strong>MFX was highly transferred to the lung tissue and this passage was remarkably higher in male rats. However, DEX administration increased the plasma concentration of MFX in both male and female rats but did not change its passage to the lung. However, there is a need for a more detailed investigation of the difference in the pharmacokinetics of MFX in male and female rats.</p>","PeriodicalId":10770,"journal":{"name":"Current drug metabolism","volume":" ","pages":"63-70"},"PeriodicalIF":2.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892002282271231219044508","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The simultaneous use of NSAIDs and antibiotics is recommended for bacterial diseases in human and veterinary medicine. Moxifloxacin (MFX) and dexketoprofen (DEX) can be used simultaneously in bacterial infections. However, there are no studies on how the simultaneous use of DEX affects the pharmacokinetics of MFX in rats.

Objectives: The aim of this study was to determine the effect of DEX on plasma and lung pharmacokinetics of MFX in male and female rats.

Methods: A total of 132 rats were randomly divided into 2 groups: MFX (n=66, 33 males/33 females) and MFX+DEX (n=66, 33 females/33 males). MFX at a dose of 20 mg/kg and DEX at a dose of 25 mg/kg were administered intraperitoneally. Plasma and lung concentrations of MFX were determined using the highperformance liquid chromatography-UV and pharmacokinetic parameters were evaluated by noncompartmental analysis.

Results: Simultaneous administration of DEX increased the plasma and lung area under the curve from 0 to 8 h (AUC0-8) and peak concentration (Cmax) of MFX in rats, while it significantly decreased the total body clearance (CL/F). When female and male rats were compared, significant differences were detected in AUC0-8, Cmax, CL/F and volume of distribution. The AUC0-8lung/AUC0-8plasma ratios of MFX were calculated as 1.68 and 1.65 in female rats and 5.15 and 4.90 in male rats after single and combined use, respectively.

Conclusion: MFX was highly transferred to the lung tissue and this passage was remarkably higher in male rats. However, DEX administration increased the plasma concentration of MFX in both male and female rats but did not change its passage to the lung. However, there is a need for a more detailed investigation of the difference in the pharmacokinetics of MFX in male and female rats.

右酮洛芬对莫西沙星在雄性和雌性大鼠血浆和肺中的处置动力学的影响
背景:在人类和兽医领域,建议同时使用非甾体抗炎药和抗生素治疗细菌性疾病。莫西沙星(MFX)和右酮洛芬(DEX)可同时用于细菌感染。然而,目前还没有关于同时使用 DEX 如何影响 MFX 在大鼠体内的药代动力学的研究:本研究旨在确定 DEX 对雌雄大鼠血浆和肺部 MFX 药代动力学的影响:方法:将132只大鼠随机分为2组:MFX组(n=66,33雄/33雌)和MFX+DEX组(n=66,33雌/33雄)。腹腔注射 20 毫克/千克剂量的 MFX 和 25 毫克/千克剂量的 DEX。采用高效液相色谱-紫外法测定 MFX 的血浆和肺部浓度,并通过非室分析评估药代动力学参数:结果:同时给药 DEX 增加了大鼠血浆和肺中 MFX 从 0 到 8 h 的曲线下面积(AUC0-8)和峰值浓度(Cmax),同时显著降低了全身清除率(CL/F)。雌性和雄性大鼠的 AUC0-8、Cmax、CL/F 和分布容积存在显著差异。经计算,雌性大鼠单次和联合使用 MFX 后的 AUC0-8 肺/AUC0-8 血浆比分别为 1.68 和 1.65,雄性大鼠的 AUC0-8 肺/AUC0-8 血浆比分别为 5.15 和 4.90:结论:MFX 向肺组织的转移率很高,雄性大鼠的转移率明显更高。然而,给雄性和雌性大鼠服用 DEX 会增加 MFX 的血浆浓度,但不会改变其进入肺部的途径。不过,有必要对 MFX 在雄性和雌性大鼠体内的药代动力学差异进行更详细的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current drug metabolism
Current drug metabolism 医学-生化与分子生物学
CiteScore
4.30
自引率
4.30%
发文量
81
审稿时长
4-8 weeks
期刊介绍: Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism. More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信